Coherence Neuro
Series A
Coherence develops a therapeutic neurotechnology platform that utilizes a brain-computer interface to continuously monitor and deliver targeted bioelectronic stimulation for cancer management. This system integrates advanced neurobiology, machine learning, and patented digital neural interfaces to adapt treatment in real time, aiming to modulate biological activity and improve patient quality of life.
About Coherence Neuro
FundFinder classes it as AI & ML.
Its investors also appear on FundFinder's most-active lists for Series A · AI (62 funds), Series A · DeepTech (53 funds), Series A · Hardware (12 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Coherence Neuro? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series A · Oct 2026
- Dutch Founders Fund — Dutch Founders Fund is an early-stage venture capital fund that invests in marketplaces and digital platforms across Europe. · cheques £250k – £3M
- Lux Capital — New York-based deep-tech VC investing from seed to growth at the intersection of science, technology and national security: AI, advanced manufacturing, energy, biotech and defence. · cheques £1M – £20M
- Possible Ventures — # Possible Ventures backs mission-driven teams using frontier tech # to make the impossible Possible. · cheques £250k – £500k